Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 07 Jul 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ciclesonide (Primary) ; Interferon beta-1b (Primary) ; Telmisartan (Primary) ; Vitamins
Indications COVID-19 respiratory infection
Focus Adverse reactions; Therapeutic Use
Acronyms COVERAGEFrance

01 Jul 2022 As per the results published in the Clinical Microbiology and Infection, the trial's Safety Monitoring Board reviewed the first interim analysis of the ciclesonide arm and recommended halting it for futility.
01 Jul 2022 Results assessing the efficacy of inhaled ciclesonide in reducing the risk of adverse outcomes in COVID-19 outpatients at risk of developing severe illness, published in the Clinical Microbiology and Infection.
13 Jan 2022 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com